[Double-blind clinical study of carpipramine/placebo (author's transl)].
A statistically planned double blind cross-over test with the substances 1-[3-(10,11-dihydro-5H-dibenz[b;f]-azepin-5-yl)-propyl]-4-piperidino-piperidine-4-carboxamide dihydrochloride-monohydrate (carpipramine, BAY b 4343 b) and placebo (BAY b 4343 a) was carried out on 30 long-term hospitalized schizophrenic patients. The study was evaluated by means of the kappa2-test and yielded the following results: 1. It could be statistically proved that carpipramine has a positive effect on psycho-pathological disorders in the behaviour of long-term hospitalized schizophrenic patients (kappa2 = 9.224; FG = 1; p greater than 0.05). 2. As regards the favourable influence of carpipramine on "productive" versus "non-productive" form of schizophrenia there were no differences. 3. Side effects or complications of a psychic, autonomic and/or motoric manner could not be seen. The usual laboratory tests showed no deviation from normal.
D000328:Adult; D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D001569:Benzodiazepines; D002986:Clinical Trials as Topic; D003984:Dibenzazepines / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D010919:Placebos; D012559:Schizophrenia / Q000188:drug therapy*
D014151:Anti-Anxiety Agents; D003984:Dibenzazepines; D010919:Placebos; D001569:Benzodiazepines
Klinische Prüfung von Carpipramin/Plazebo im Doppelblindversuch